iDEL Therapeutics GmbH

Founded in 2025 and based in Dortmund, Germany, iDEL Therapeutics GmbH operates as a biotechnology company that provides a synthetic shuttle drug delivery platform to transport therapeutic payloads directly into the cytosol of tumor cells. Based in Germany, iDEL Therapeutics GmbH develops a synthetic shuttle drug delivery platform to transport therapeutic payloads directly into the cytosol of tumor cells. iDEL Therapeutics GmbH is focused on creating advanced synthetic shuttle technologies for cancer therapy. Founded in 2025 in Dortmund, Germany, the company has executed one deal as of March 2026.

In its first funding round, iDEL raised EUR 9 million in a SEED round led by BioMed Partners, with additional participation from NRW. Venture, Grunderfonds Ruhr, and Khanu Management. Marcus Kostka co-founder guide iDEL Therapeutic's vision. iDEL Therapeutics specializes in developing a novel synthetic shuttle platform for the direct delivery of therapeutic payloads into tumor cell cytosol.

This technology targets previously inaccessible cancer drivers, enhancing the efficacy of treatments for various cancer indications. Their lead candidates focus on intracellular oncogene targeting and multicancer drug conjugates, currently in preclinical evaluation. iDEL’s therapies aim to provide enhanced treatment options for patients with a wide range of solid tumors in markets including North America, Europe, and select Asia-Pacific countries. iDEL Therapeutics generates revenue through partnerships and collaborations with life science investors and healthcare organizations.

Their business model relies on strategic alliances to develop and commercialize therapeutic products, facilitating shared investment in research and clinical trials. Revenue opportunities may arise from cooperative agreements with milestone payments tied to the advancement of product candidates, as well as potential licensing agreements or royalties from future sales, positioning iDEL to broaden its market reach and therapeutic offerings. In October 2026, iDEL Therapeutics GmbH successfully raised EUR 9 million in SEED funding, which will support the development of new therapeutic products aimed at improving cancer treatment efficacy. The company plans to expand its market presence in North America and Europe, targeting the high prevalence of cancer in these regions.

The recent funding will assist in advancing their product pipeline through clinical stages, ultimately enhancing their capacity to address unmet medical needs in oncology.